PE20081361A1 - Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas - Google Patents

Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas

Info

Publication number
PE20081361A1
PE20081361A1 PE2007001144A PE2007001144A PE20081361A1 PE 20081361 A1 PE20081361 A1 PE 20081361A1 PE 2007001144 A PE2007001144 A PE 2007001144A PE 2007001144 A PE2007001144 A PE 2007001144A PE 20081361 A1 PE20081361 A1 PE 20081361A1
Authority
PE
Peru
Prior art keywords
solvent
clonazepam
clonazepan
percentage
weight
Prior art date
Application number
PE2007001144A
Other languages
English (en)
Spanish (es)
Inventor
Gene Jamieson
Jardin Michael Des
Clark Allphin
Original Assignee
Jazz Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals filed Critical Jazz Pharmaceuticals
Publication of PE20081361A1 publication Critical patent/PE20081361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2007001144A 2006-08-28 2007-08-23 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas PE20081361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84056806P 2006-08-28 2006-08-28

Publications (1)

Publication Number Publication Date
PE20081361A1 true PE20081361A1 (es) 2008-11-06

Family

ID=38819711

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001144A PE20081361A1 (es) 2006-08-28 2007-08-23 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas

Country Status (17)

Country Link
US (2) US8609651B2 (enExample)
EP (2) EP2068933A2 (enExample)
JP (2) JP2010502614A (enExample)
KR (1) KR20090043603A (enExample)
CN (1) CN101528261B (enExample)
AR (1) AR062556A1 (enExample)
AU (1) AU2007290589B2 (enExample)
BR (1) BRPI0714907A2 (enExample)
CA (1) CA2662197A1 (enExample)
IL (1) IL197275A0 (enExample)
MX (1) MX2009002310A (enExample)
NO (1) NO20091211L (enExample)
NZ (2) NZ595388A (enExample)
PE (1) PE20081361A1 (enExample)
TW (1) TW200824693A (enExample)
UY (1) UY30561A1 (enExample)
WO (2) WO2008027357A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP2121025B1 (en) * 2007-01-19 2016-11-02 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
TW200922635A (en) * 2007-08-31 2009-06-01 Archimedes Dev Ltd Non-aqueous pharmaceutical compositions
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP2012525402A (ja) * 2009-04-28 2012-10-22 オプトメッド インコーポレイテッド 過活動膀胱およびそれに関連する状態を、治療するおよび予防するための、組成物および方法
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
SG193958A1 (en) * 2011-03-31 2013-11-29 Acorda Therapeutics Inc Intranasal benzodiazepine pharmaceutical compositions
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US20160000702A1 (en) * 2013-02-22 2016-01-07 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines
KR101635635B1 (ko) * 2014-12-04 2016-07-01 주식회사 엘지생활건강 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물
CA2987242C (en) 2015-05-25 2023-10-10 Isotherapeutics Group, Llc Dotmp kit formulations for radioisotopes
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3551189B1 (en) * 2016-12-09 2023-11-01 Alexza Pharmaceuticals, Inc. Alprazolam for use in treating epilepsy
MX2020005169A (es) * 2017-11-17 2020-12-03 Neurana Pharmaceuticals Inc Métodos de administración de tolperisona.
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
US10896106B2 (en) 2018-05-10 2021-01-19 Teradyne, Inc. Bus synchronization system that aggregates status
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US20200338090A1 (en) * 2019-04-29 2020-10-29 Marsh and Wang Medical Systems, LLC Seizure control compositions and methods of using same
CN110420190B (zh) * 2019-08-29 2021-07-09 湖南洞庭药业股份有限公司 氯硝西泮片及其制备方法
CA3221395A1 (en) * 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
CN115707451A (zh) * 2021-08-19 2023-02-21 北京万全德众医药生物技术有限公司 氯硝西泮口服溶液
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN114656410A (zh) * 2022-03-02 2022-06-24 济南同路医药科技发展有限公司 一种氯硝西泮杂质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266466A (en) * 1987-01-14 1993-11-30 President And Fellows Of Harvard College Method of using T7 DNA polymerase to label the 3' end of a DNA molecule
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
FR2656303B1 (fr) 1989-12-26 1994-06-10 Parke Davis Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
DK0532546T3 (da) * 1990-05-10 1998-12-28 Nycomed Pharma As Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler
DE4021263C2 (de) 1990-07-04 1996-04-11 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
FR2692174B1 (fr) 1992-06-16 1994-08-19 Valois Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide.
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU2345695A (en) * 1994-04-28 1995-11-29 F. Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
DE19756442A1 (de) * 1997-12-18 1999-06-24 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
CA2379365C (en) * 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
DE19938798A1 (de) * 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) * 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
FR2815611B1 (fr) * 2000-10-23 2003-04-11 Valois Sa Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
EP1422228A1 (en) * 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
JP2005519075A (ja) 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
US6742677B2 (en) 2002-04-18 2004-06-01 Valois S.A.S. Fluid dispenser pump
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
ITRM20020357A1 (it) 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
SI1587514T1 (sl) 2003-01-31 2006-10-31 Orexo Ab Hitro ucinkujoc farmacevtski sestavek
CN100421649C (zh) 2003-06-17 2008-10-01 Sk株式会社 含地西泮的经鼻微乳
CA2538856C (en) * 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
PL1848403T3 (pl) 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
US20070021411A1 (en) 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US9319244B2 (en) 2010-12-22 2016-04-19 Usablenet Inc. Methods for emailing labels as portable data files and devices thereof

Also Published As

Publication number Publication date
KR20090043603A (ko) 2009-05-06
CN101528261A (zh) 2009-09-09
JP2010502614A (ja) 2010-01-28
AU2007290589A1 (en) 2008-03-06
NZ575744A (en) 2011-10-28
EP2056877A2 (en) 2009-05-13
JP2010502612A (ja) 2010-01-28
WO2008027357A2 (en) 2008-03-06
BRPI0714907A2 (pt) 2014-08-19
US20080076761A1 (en) 2008-03-27
MX2009002310A (es) 2009-09-21
CA2662197A1 (en) 2008-03-06
US8716279B2 (en) 2014-05-06
US8609651B2 (en) 2013-12-17
TW200824693A (en) 2008-06-16
US20080070904A1 (en) 2008-03-20
NZ595388A (en) 2011-12-22
UY30561A1 (es) 2008-03-31
WO2008027395A2 (en) 2008-03-06
IL197275A0 (en) 2009-12-24
NO20091211L (no) 2009-05-27
WO2008027357A3 (en) 2008-04-17
CN101528261B (zh) 2012-07-18
EP2068933A2 (en) 2009-06-17
AU2007290589B2 (en) 2012-04-05
WO2008027395A3 (en) 2008-04-17
AR062556A1 (es) 2008-11-19
WO2008027357A9 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
AR062556A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
BRPI0714399B8 (pt) composição farmacêutica líquida oral
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
CO7111300A2 (es) Formulación de anticuerpos
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
PE20070643A1 (es) Composiciones farmaceuticas que comprenden buprenorfina
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
AR069572A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids

Legal Events

Date Code Title Description
FC Refusal